Short Interest in CymaBay Therapeutics Inc. (CBAY) Declines By 28.7%

CymaBay Therapeutics Inc. (NASDAQ:CBAY) was the recipient of a significant decrease in short interest in May. As of May 31st, there was short interest totalling 545,881 shares, a decrease of 28.7% from the May 15th total of 765,237 shares. Approximately 2.2% of the shares of the company are short sold. Based on an average trading volume of 298,164 shares, the short-interest ratio is currently 1.8 days.

Several equities research analysts have issued reports on CBAY shares. Piper Jaffray Companies increased their target price on CymaBay Therapeutics from $5.00 to $6.50 and gave the stock an “overweight” rating in a research report on Friday, March 24th. HC Wainwright restated a “buy” rating and set a $7.00 target price (up previously from $6.00) on shares of CymaBay Therapeutics in a research report on Monday, March 27th. Zacks Investment Research downgraded CymaBay Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, April 3rd. Finally, ValuEngine upgraded CymaBay Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $5.25.

Shares of CymaBay Therapeutics (NASDAQ CBAY) opened at 5.09 on Wednesday. The firm’s 50 day moving average price is $4.21 and its 200 day moving average price is $3.21. CymaBay Therapeutics has a 52-week low of $1.15 and a 52-week high of $5.33. The stock’s market cap is $146.35 million.

CymaBay Therapeutics (NASDAQ:CBAY) last issued its quarterly earnings data on Thursday, May 11th. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.07. The business had revenue of $4.79 million for the quarter. On average, analysts expect that CymaBay Therapeutics will post ($0.86) EPS for the current year.

Several large investors have recently modified their holdings of the stock. J. Goldman & Co LP acquired a new stake in shares of CymaBay Therapeutics during the fourth quarter worth about $571,000. Acadian Asset Management LLC acquired a new stake in shares of CymaBay Therapeutics during the first quarter worth about $129,000. TFS Capital LLC acquired a new stake in shares of CymaBay Therapeutics during the first quarter worth about $169,000. ClariVest Asset Management LLC acquired a new stake in shares of CymaBay Therapeutics during the first quarter worth about $105,000. Finally, Vanguard Group Inc. increased its stake in shares of CymaBay Therapeutics by 55.7% in the first quarter. Vanguard Group Inc. now owns 821,507 shares of the biopharmaceutical company’s stock worth $3,532,000 after buying an additional 293,823 shares during the last quarter. 36.87% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: This piece was originally reported by Transcript Daily and is the property of of Transcript Daily. If you are reading this piece on another publication, it was stolen and republished in violation of U.S. & international trademark & copyright laws. The correct version of this piece can be viewed at https://transcriptdaily.com/2017/06/21/short-interest-in-cymabay-therapeutics-inc-cbay-declines-by-28-7.html.

About CymaBay Therapeutics

CymaBay Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. The Company’s product candidates include Arhalofenate, MBX-8025 and MBX-2982. Arhalofenate is used to treat gout.

Receive News & Ratings for CymaBay Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply